Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie přípravku IBI3003 u pacientů s relabujícím nebo refrakterním mnohočetným myelomem

22. září 2026 aktualizováno: Fortvita Biologics (USA)Inc.

Fáze I/II, multicentrická, otevřená studie přípravku IBI3003 u účastníků s relabujícím nebo refrakterním mnohočetným myelomem

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

Přehled studie

Postavení

Nábor

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

360

Fáze

  • Fáze 2
  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Arizona
      • Scottsdale, Arizona, Spojené státy, 85258
        • Aktivní, ne nábor
        • Honor Health
    • California
      • Duarte, California, Spojené státy, 91010
      • Irvine, California, Spojené státy, 92618
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30322
        • Aktivní, ne nábor
        • Emory
    • New York
      • New York, New York, Spojené státy, 10021
    • Texas
      • Houston, Texas, Spojené státy, 77030

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria

Participants in Parts 1 & 2 must satisfy all of the following criteria to be enrolled in the study:

  1. Age ≥18 years.

  2. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.

    Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and any one or more of the following myelomadefining events:

    • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or corrected serum calcium >2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
    • Any one or more of the following biomarkers of malignancy:

    Clonal bone marrow plasma cell percentage ≥60% Involved: uninvolved serum free light chain ratio ≥100 (involved FLC level must be

    ≥100 mg/L) >1 focal lesions on MRI studies (at least 5 mm in size)

  3. Relapsed or refractory measurable multiple myeloma (R/R MM) following prior treatment with ≥3 lines of systemic anti-myeloma therapy that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy, and with limited or no therapeutic options that are likely to offer a favorable risk/benefit profile; participants must be relapsed or refractory to their last anti-myeloma regimen.

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

  5. At least one of the following measurable disease indicators:

    • Serum M-protein ≥5 g/L (for IgA and IgD subtypes, quantitative immunoglobin measurements could be used as substitutions for M-protein)
    • Urine M-protein ≥200 mg/24h
    • Serum free light chain (FLC) test: affected FLC level ≥100 mg/L and abnormal serum FLC ratio (<0.26 or >1.65)
  6. Adequate hematologic, hepatic, renal and cardiac function:

    • Blood count: absolute neutrophil count ≥1.0×10^9/L, hemoglobin ≥70 g/L, and platelet count ≥50×10^9/L (values must be achieved without growth factors or blood transfusions within 7 days prior to first dose)
    • Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤2.5× upper limit of normal (ULN) and total bilirubin (TBIL) ≤1.5×ULN
    • Renal function: calculated creatinine ≥30 mL/min by the Cockcroft-Gault Equation
    • Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%
  7. Life expectancy ≥3 months.

  8. Women of childbearing potential and fertile men who are sexually active must agree to use a highly effective method of contraception (<1% / year failure rate) during the study and for 90 days after the last dose level of study drug. Contraception must be consistent with local regulations or standards regarding the use of birth control methods by participants participating in clinical trials. Women and men must agree not to donate or bank eggs (ova, oocytes) or sperm, respectively, during the study and for 90 days after the last dose level of study drug.

  9. Participants with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.

  10. Willing and able to adhere to the complete schedule of assessments and all prohibitions and restrictions specified in this protocol

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.

  2. Active amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or solitary plasmacytoma, or smoldering multiple myeloma (MM) as defined by the IMWG criteria.

  3. Spinal cord compression that results in limited self-care at present or within 6 months prior to informed consent, or that is expected to cause such limitations during Study participation.

  4. History of primary immunodeficiency.

  5. Current or previous other malignancy within 3 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.

  6. Allogeneic hematopoietic stem cell transplantation within the last 6 months, or autologous stem cell transplantation within the last 3 months prior to the first administration of the study drug.

  7. History of organ transplantation.

  8. Active graft-versus-host disease.

  9. Thromboembolism or cerebrovascular events (e.g., myocardial infarction, unstable angina, transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with complications of central venous access], or pulmonary embolism) within 6 months prior to the first dose of study drug.

  10. Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.

  11. Known allergies, hypersensitivity, or intolerance to IBI3003 or its excipients (refer to Investigator's Brochure).

  12. Prior toxicities that have not resolved to ≤Grade 1 prior to study treatment administration except for stable chronic toxicities (≤Grade 2) not expected to resolve (e.g., stable Grade 2 peripheral neurotoxicity)

  13. Prior antitumor therapy as follows, prior to the first dose of study drug:

    • Gene modified adoptive cell therapy (e.g., chimeric antigen receptor modified T cells, natural killer cells) within 8 weeks.
    • Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer.
    • Antibody treatment (e.g., monoclonal antibody, bispecific antibody) for multiple myeloma within 21 days.
    • Cytotoxic therapy (including antibody-drug conjugates) within 14 days.
    • Proteasome inhibitor therapy within 14 days Immunomodulatory agent therapy within 7 days.
    • Radiotherapy within 21 days. However, if the radiation field covered ≤5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy.
    • Cancer vaccine received within 3 months.
  14. Use of immunosuppressive therapy within 28 days of the start date of study treatment.

    Immunosuppressive therapy includes, but is not limited to, cyclosporine A, tacrolimus, and mycophenolate mofetil, but does not include corticosteroids given as part of an antimyeloma regimen. Participants receiving corticosteroids must be at a dose level ≤10 mg/day of prednisone equivalent for at least 7 days prior to the start of study treatment administration.

  15. Live or live attenuated vaccine administered within 4 weeks prior to start of study treatment, or anticipated need for live or live attenuated vaccine during the study.

  16. Uncontrolled diseases, including:

    • Uncontrolled infection or infection requiring systemic antibiotics, antivirals or antifungals within one week prior to first administration of the study drug;
    • Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
    • For participants in mainland China, acute or chronic active hepatitis B (HBsAg positive and/or HBcAb positive with HBV DNA titer ≥104 copies/mL or ≥2000 IU/mL) or C (HCV Ab positive with HCV RNA>103 copies/mL). For participants outside of mainland China, active, latent or incompletely treated infection with HBV or HCV;
    • Failed to complete anti-tuberculosis therapy at any point prior to C1D1; active tuberculosis infection, or still on anti-tuberculosis therapy;
    • Active syphilis infection requiring treatment;
    • Symptomatic congestive heart failure Grade II-IV (New York Heart Association [NYHA]), symptomatic or uncontrolled arrhythmias, QTc interval (calculate using the Fridericia formula) >480 ms, or personal or family history of congenital long/short QT syndrome;
    • Uncontrollable hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg);
    • Active autoimmune diseases, including but not limited to inflammatory bowel disease, autoimmune hepatitis, demyelinating lesions, extensive dermatitis, immunerelated interstitial pneumonia, or Grave's disease requiring antithyroid medication control (vitiligo, or hypothyroidism requiring hormone replacement therapy, type I diabetes requiring only insulin replacement therapy and no other systemic therapy in the past 2 years are eligible); Presence of clinically uncontrolled pleural/peritoneal effusions (participants who do not require regular drainage or who do not demonstrate significant re-accumulation of effusion for at least 72 hours after the most recent drainage can enroll).
  17. Major surgery within 2 weeks prior to the first dose of study treatment, not fully recovered from any prior surgery, or has non-minor surgery anticipated during the time the participant is expected to receive study drug or within 2 weeks after the last dose of study drug administration.

  18. Participating in any other interventional clinical research except an observational (noninterventional) study or the survival follow-up phase of an interventional study.

  19. Currently pregnant or breastfeeding.

  20. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

  21. Inability to comprehend or unwilling to sign the ICF

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: IBI3003

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Adverse events (AEs)
Časové okno: Up to 30 days post last dose

Number of patients who Experienced related AEs from the first dose until 30 days after the last dose

Up to 30 days post last dose
Dose limiting toxicities (DLTs)
Časové okno: Up to 28 days post first dose

To evaluate the safety and tolerability of IBI3003

Up to 28 days post first dose
ORR
Časové okno: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003
Časové okno: up to 24 months

To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003

up to 24 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence and characterization of anti-drug antibody (ADA).
Časové okno: up to 24 months

To evaluate the immunogenicity of IBI3003

up to 24 months
Preliminary efficacy including objective response rate (ORR)
Časové okno: up to 24 months

objective response rate. To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To evaluate minimal residual disease (MRD) negativity rates. MRD negativity rate.
Časové okno: up to 24 months

To evaluate minimal residual disease (MRD) negativity rates.

up to 24 months
efficacy estimates sCRR
Časové okno: up to 24 months

stringent complete response rate. To evaluate other efficacy estimates of IBI3003 in the participant population.

up to 24 months
Incidence of TEAEs
Časové okno: up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
half-life (T1/2)
Časové okno: up to 24 months

To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
time to maximum concentration (Tmax)
Časové okno: up to 24 months

time to peak concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
maximum concentration (Cmax)
Časové okno: peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months

peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.
area under the curve (AUC)
Časové okno: up to 24 months

area under the curve. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
complete response rate (CRR)
Časové okno: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
very good partial response rate (VGPRR)
Časové okno: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
duration of response (DoR)
Časové okno: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
disease control rate (DCR)
Časové okno: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
time to response (TTR)
Časové okno: To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.
progression free survival (PFS).
Časové okno: up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
SAEs
Časové okno: up to 24 months

serious adverse events (SAEs) Adverse events will be assessed by investigator(s) To evaluate the safety of IBI3003 in the participant population.

up to 24 months
changes in laboratory parameters
Časové okno: up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
physical examination findings
Časové okno: up to 24 months

A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.To evaluate the safety of IBI3003 in the participant population.

up to 24 months
vital signs
Časové okno: up to 24 months

Collection of vital signs will include temperature in ℃, measurement tool is physiological parameter.To evaluate the safety of IBI3003 in the participant population.

up to 24 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

30. září 2026

Primární dokončení (Odhadovaný)

30. června 2027

Dokončení studie (Odhadovaný)

30. září 2028

Termíny zápisu do studia

První předloženo

8. ledna 2026

První předloženo, které splnilo kritéria kontroly kvality

12. ledna 2026

První zveřejněno (Aktuální)

13. ledna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

25. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

22. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit